MARKET

VIR

VIR

Vir Biotechnology, Inc.
NASDAQ
30.14
+0.23
+0.77%
After Hours: 30.00 -0.14 -0.46% 18:20 02/03 EST
OPEN
29.91
PREV CLOSE
29.91
HIGH
30.95
LOW
29.35
VOLUME
859.26K
TURNOVER
0
52 WEEK HIGH
34.97
52 WEEK LOW
18.05
MARKET CAP
4.01B
P/E (TTM)
3.545
1D
5D
1M
3M
1Y
5Y
GSK Q4 sales driven by vaccines as specialty medicines see decline; provides FY23 outlook
Seeking Alpha · 2d ago
5 Value Stocks In The Healthcare Sector
Benzinga · 4d ago
Vir upgraded at Morgan Stanley citing multiple catalysts in 2023
Seeking Alpha · 01/27 16:54
SVB Securities Keeps Their Buy Rating on Vir Biotechnology (VIR)
TipRanks · 01/27 12:25
Analyst Expectations for Vir Biotechnology's Future
Benzinga · 01/27 12:01
SVB Leerink Maintains Outperform on Vir Biotechnology, Lowers Price Target to $43
Benzinga · 01/27 11:49
Morgan Stanley Upgrades Vir Biotechnology to Equal-Weight, Raises Price Target to $30
Benzinga · 01/27 11:28
--Morgan Stanley Upgrades Vir Biotechnology to Equal Weight From Underweight, Adjusts Price Target to $30 From $18
--Morgan Stanley Upgrades Vir Biotechnology to Equal Weight From Underweight, Adjusts Price Target to $30 From $18
MT Newswires · 01/27 09:54
More
About VIR
Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. It is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.

Webull offers kinds of Vir Biotechnology Inc stock information, including NASDAQ:VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.